{
    "2021-03-31": [
        [
            {
                "time": "",
                "original_text": "【银河医药孟令伟/刘晖】公司点评丨万泰生物 (603392)：IVD+疫苗双轮驱动，业绩高速增长",
                "features": {
                    "keywords": [
                        "万泰生物",
                        "IVD",
                        "疫苗",
                        "双轮驱动",
                        "业绩高速增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}